BioInvent International AB is a clinical-stage biotech company that discovers and develops novel and immuno-modulatory antibodies for cancer therapy. The company is headquartered in Lund, Skane and currently employs 109 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenue
226
226
44
71
326
19
Revenue Growth (YoY)
413.99%
413.99%
-38%
-78%
1,616%
-87%
Cost of Revenue
--
--
--
--
--
--
Gross Profit
--
--
--
--
--
--
Selling, General & Admin
73
73
56
50
49
38
Research & Development
504
504
439
374
312
244
Operating Expenses
578
578
515
442
376
297
Other Non Operating Income (Expenses)
--
--
--
--
--
--
Pretax Income
-332
-332
-429
-330
-42
-278
Income Tax Expense
0
0
0
0
0
0
Net Income
-332
-332
-429
-330
-42
-278
Net Income Growth
-22%
-23%
30%
686%
-85%
266%
Shares Outstanding (Diluted)
65.86
65.78
65.8
65.76
61.52
54.16
Shares Change (YoY)
0%
0%
0%
7%
14%
89%
EPS (Diluted)
-5.05
-5.06
-6.52
-5.02
-0.69
-5.14
EPS Growth
-23%
-22%
30%
627%
-87%
93%
Free Cash Flow
-257
-257
-390
-351
-52
-259
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
--
--
--
--
--
--
Operating Margin
-155.3%
-155.3%
-1,070.45%
-521.12%
-15.33%
-1,463.15%
Profit Margin
-146.9%
-146.9%
-975%
-464.78%
-12.88%
-1,463.15%
Free Cash Flow Margin
-113.71%
-113.71%
-886.36%
-494.36%
-15.95%
-1,363.15%
EBITDA
-332
-332
-452
-354
-36
-264
EBITDA Margin
-146.9%
-146.9%
-1,027.27%
-498.59%
-11.04%
-1,389.47%
D&A For EBITDA
19
19
19
16
14
14
EBIT
-351
-351
-471
-370
-50
-278
EBIT Margin
-155.3%
-155.3%
-1,070.45%
-521.12%
-15.33%
-1,463.15%
Effective Tax Rate
0%
0%
0%
0%
0%
0%
Follow-Up Questions
What are BioInvent International AB (publ)'s key financial statements?
According to the latest financial statement (Form-10K), BioInvent International AB (publ) has a total asset of $671, Net loss of $-332
What are the key financial ratios for BOVNF?
BioInvent International AB (publ)'s Current ratio is 5.93, has a Net margin is -146.9, sales per share of $3.43.
How is BioInvent International AB (publ)'s revenue broken down by segment or geography?
BioInvent International AB (publ) largest revenue segment is Pharmaceutical, at a revenue of 44,686,000 in the most earnings release.For geography, United States is the primary market for BioInvent International AB (publ), at a revenue of 36,822,000.
Is BioInvent International AB (publ) profitable?
no, according to the latest financial statements, BioInvent International AB (publ) has a net loss of $-332
Does BioInvent International AB (publ) have any liabilities?
yes, BioInvent International AB (publ) has liability of 113
How many outstanding shares for BioInvent International AB (publ)?
BioInvent International AB (publ) has a total outstanding shares of 65.8